MyoKardia Inc. | Ownership
Companies that own MyoKardia Inc.
Fidelity Management & Research Co.
5,929,912
14.78%
563,367
0.04%
06/30/2018
Wellington Management Co. LLP
3,222,609
8.02%
-123,009
0.04%
06/30/2018
BlackRock Fund Advisors
2,448,015
6.1%
741,305
0.01%
06/30/2018
T. Rowe Price Associates, Inc.
2,365,908
5.9%
368,147
0.02%
06/30/2018
The Vanguard Group, Inc.
2,192,572
5.47%
566,736
0%
06/30/2018
Partner Fund Management LP
2,020,915
5.04%
179,169
2.16%
07/03/2018
Farallon Capital Management LLC
1,481,278
3.69%
442,000
0.6%
06/30/2018
Deerfield Management Company LP
1,159,000
2.89%
90,320
2.04%
06/30/2018
Perceptive Advisors LLC
1,089,169
2.72%
254,490
1.53%
06/30/2018
Hillhouse Capital Management Ltd. (Hong Kong)
858,340
2.14%
100,000
0.6%
06/30/2018
| Address |
333 Allerton Avenue
San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.myokardia.com |
| Updated |
07/08/2019 |
| MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. |
